StockCIK 1818794

Dyne Therapeutics, Inc. (DYN): Insider Trades and Fund Holdings

In the past 12 months, Dyne Therapeutics, Inc. insiders reported 1 open-market purchase worth $40K and 11 sales worth $65.7M; 11 of the sales were reported as made under a 10b5-1 trading plan.

1Insider buys, 12 months

$40KBought by insiders, 12 months

$65.7MSold by insiders, 12 months

1Tracked funds holding

Recent insider trades

Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Oct 6, 2026.

Recent DYN insider trades
Filed	Traded	Insider	Role	Type	Shares	Price ($)	Value	Holding	Filing
Oct 6	Oct 2	Brian S. PosnerDirector	Director	▲ BUY	2,500	16.00	$40K	+10%	Form 4 ↗
Sep 8	Sep 8	John CoxCEO	CEO	▼ SELL10b5-1	5,658	18.88	$107K	−1.6%	Form 4 ↗
Sep 8	Sep 4	Douglas KerrChief Medical Officer	Chief Medical Officer	▼ SELL10b5-1	3,745	24.35	$91K	−2.2%	Form 4 ↗
Sep 8	Sep 8	Douglas KerrChief Medical Officer	Chief Medical Officer	▼ SELL10b5-1	1,290	18.88	$24K	−0.8%	Form 4 ↗
Sep 8	Sep 4	Johanna Friedl-NadererChief Commercial Officer	Chief Commercial Officer	▼ SELL10b5-1	900	24.35	$22K	−0.6%	Form 4 ↗
Sep 8	Sep 8	Johanna Friedl-NadererChief Commercial Officer	Chief Commercial Officer	▼ SELL10b5-1	185	18.88	$3K	−0.1%	Form 4 ↗
Aug 17	Aug 14	Jason P. RhodesDirector	Director (ind.)	▼ SELL10b5-1	2,160,516	25.00	$54.0M	−83%	Form 4 ↗
Aug 17	Aug 13	Jason P. RhodesDirector	Director (ind.)	▼ SELL10b5-1	426,412	26.20	$11.2M	−36%	Form 4 ↗
Aug 17	Aug 13	John CoxCEO	CEO	▼ SELL10b5-1	4,986	26.28	$131K	−1.4%	Form 4 ↗
Aug 17	Aug 13	Erick LuceraCFO	CFO	▼ SELL10b5-1	1,797	26.28	$47K	−1.5%	Form 4 ↗

Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings

All 12 DYN insider trades →

Insiders who traded in the past year

Insider	Role	Buys	Bought	Sells	Sold	Latest
Brian S. Posner	Director	1	$40K	0	$0	Oct 6, 2026
John Cox	CEO	0	$0	2	$238K	Sep 8, 2026
Douglas Kerr	Chief Medical Officer	0	$0	3	$156K	Sep 8, 2026
Johanna Friedl-Naderer	Chief Commercial Officer	0	$0	3	$31K	Sep 8, 2026
Jason P. Rhodes	Director	0	$0	2	$65.2M	Aug 17, 2026
Erick Lucera	CFO	0	$0	1	$47K	Aug 17, 2026

Tracked funds that report DYN

From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.

Fund	Quarter	Shares	Value	% of portfolio	Change
Renaissance Technologies	Q2 2026	360,572	$8.01M	0.01%	▼ −32.4%

Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings

Reading these numbers

Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →